查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715772

病毒载体製造市场（按载体类型、工作流程、交付方式、技术、适应症、应用和最终用户）—2025-2030 年全球预测

Viral Vector Manufacturing Market by Vector Type, Workflow, Delivery Method, Technology, Disease Indication, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年病毒载体製造市场价值为 91.9 亿美元，预计 2025 年将成长至 110 亿美元，复合年增长率为 20.03%，预计到 2030 年将达到 275 亿美元。

介绍

主要市场统计数据
基准年2024年 91.9亿美元
预计年份：2025年 110亿美元
预测年份 2030 275亿美元
复合年增长率（%） 20.03%

近年来，病毒载体製造的动态部分已成为先进治疗方法和突破性生物医学研究的关键。创新技术、严谨的科学研究和不断发展的法律规范的结合正在加速病毒载体在不同治疗领域的开发和应用。这项变革格局的特点是强劲成长，这得益于对个人化医疗、基因疗法和疫苗的需求不断增长。手术精度的流程优化和严格的品管措施确保这些载体符合最高的安全性和有效性标准。

我们将标靶治疗从实验室带到临床的能力依赖于不断改进的复杂製造流程。上游和下游製程的进步使製造商能够在不损害产品完整性的情况下实现可扩展性和业务效率。因此，随着生物治疗产业朝着更易于获取和更有效的未来迈进，大量市场研究强调了利用尖端製造技术和法规遵循的重要性。

病毒载体製造的历程不仅是技术进步的历程，也是策略市场定位的历程。随着投资者兴趣的不断增长以及数位技术在品质保证中的整合，该生态系统已准备好在多个疾病领域持续创新和更广泛地应用。本介绍性概述将深入探讨定义这一快速发展的製造业格局的多方面细分市场、新兴趋势以及关键区域和企业倡议。

改变病毒载体製造市场

病毒载体製造的当前环境正在经历一场变革性转变，这种转变正在重塑老牌产业参与企业和新兴企业应对製造挑战和市场机会的方式。快速的技术进步和下一代生物加工技术的整合彻底改变了载体的设计、最佳化和部署方式。产业领导者透过采用模组化製造策略和利用流程自动化不断适应这些变化。

自动化和即时分析的重大发展正在开启业务效率的新时代。这种不断发展的情况更加重视跨多个生产阶段的流程整合，从而整合先前孤立的工作流程。同时，不断发展的监管和品质保证框架继续推动製造商采用严格的验证方法，即使是最复杂的产品也可以在不影响品质或安全的情况下快速扩大规模。

除了技术范式之外，一个值得注意的趋势是经营模式的多样化。许多公司正在从传统的线性生产路径转向更灵活、可自订的平台，以灵活回应市场需求。对先进精製技术和新型转染方法等新子领域的策略性投资不仅重新定义了产品生命週期，也为临床成功和商业性可行性设定了新的基准。这段前所未有的变革时期凸显了持续进行策略重新评估和创新的必要性，这不仅可以促进卓越运营，还可以提供抓住全球市场机会的竞争优势。

此外，产业趋势反映出人们越来越意识到生技药品生产基地所面临的业务挑战和巨大机会。如今，重点是将数位解决方案与传统製造技术相结合，创建能够抵御市场波动并适应不断变化的研究需求的混合模式。总的来说，这些变革性的变化为未来铺平了道路，病毒载体製造不仅能满足日益增长的全球健康需求，而且还能透过效率、永续性和精确性的视角来实现。

关键细分洞察

病毒载体製造市场区隔复杂，相关人员可以识别具有重大创新和机会的细分市场。仔细观察按载体类型分類的情况，可以发现多种方法，包括腺病毒载体、桿状病毒载体、单纯疱疹病毒载体、慢病毒载体、质体DNA 和逆转录病毒的研究。这些特定类别突显了标靶治疗中采用的多种遗传元素和传递机制，对于根据临床需求客製化生产策略至关重要。

除了向量类型之外，市场细分还将透过工作流程来呈现，其特点是下游流程和上游流程之间的分叉。下游加工分为配方和精製，每个步骤对于维持产品稳定性和法规遵循至关重要。同时，上游製程进一步透过使用反应器、细胞培养系统和客製化培养基配方进行分类，从而实现载体生产的放大和优化的高级客製化。

此外，透过递送方法进行细分的细緻方法凸显了体外和体内应用的双重策略。在体外空间，重点是细胞再输注和细胞递送技术，以优化治疗载体与人体外部标靶细胞的整合。相反，直接注射、静脉注射和口服给药等体内方法对于确保有效的载体递送和体内转基因表达至关重要。每条途径都有独特的挑战和优势，需要操作和临床的考量。

按技术进行细分可以进一步提高市场分析的细微度。这些包括精製技术和转染方法，前者又细分为层析法和超过滤。后者分为以化学为基础的方法和电穿孔，在考虑产品产量和纯度时，每种方法都有不同的操作优势和技术挑战。如此详细的细分凸显了能够适应临床和工业应用不断变化的需求的客製化製造流程的重要性。

此外，按适应症进行市场细分可以带来解决多样化治疗环境的见解。每种疾病，包括心血管疾病、遗传疾病、感染疾病和代谢疾病，都需要专门的载体设计和生产方法。此外，基于应用的细分透过关注基因治疗、癌症研究和疫苗治疗提供了市场动态的详细视图。在基因治疗中，进一步分为遗传疾病、肿瘤疾病和单基因突变，揭示了个人化医疗的针对性方法。类似地，肿瘤学研究领域透过基因惰性、溶瘤病毒疗法和肿瘤抑制基因等细分来描述，而疫苗学则透过癌症疫苗、感染疾病和通用感染疾病领域来绘製。

最后，根据最终用户概况进行的市场细分为了解行业的多样化需求提供了关键见解。分析涵盖生物技术公司、製药公司和研究机构。生技领域分为大型公司和新兴企业，而製药公司则专注于两个领域：製造和研发。同样，研究机构也分为学术实验室和政府实验室。这种分解不仅使相关人员能够有效地分配资源和优化生产方法，而且还推动了与临床和商业需求紧密结合的有针对性的创新。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 病毒载体在感染疾病疫苗生产的应用日益增多
      • 专注于个人化医疗和基因治疗
      • 政府支持加强全球病毒载体生产能力
    • 限制因素
      • 生产成本高，原料不均匀
    • 机会
      • 增强视网膜结构和功能疾病的基因治疗解决方案
      • 投资可扩展的製造工艺，实现病毒载体的大规模生产
    • 任务
      • 复杂的法规环境确保遵守世界各地的各种标准
  • 市场区隔分析
    • 载体类型：腺病毒载体由于其强大的免疫抗原性原性和感染非分裂细胞的能力，越来越多地用于疫苗和基因治疗
    • 应用：基因治疗在治疗遗传疾病和肿瘤疾病的需求增加
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

6. 病毒载体製造市场（依载体类型）

  • 介绍
  • 腺病毒载体
  • 桿状病毒载体
  • 单纯疱疹病毒载体
  • 慢病毒载体
  • 质体DNA
  • 逆转录病毒

7. 病毒载体製造市场（依工作流程）

  • 介绍
  • 下游加工
    • 配方
    • 精製
  • 上游处理
    • 反应器
    • 细胞培养系统
    • 培养基配方

8. 病毒载体製造市场（以交付方式）

  • 介绍
  • Ex Vivo
    • 细胞再注射
    • 细胞转导
  • In vivo
    • 缸内直喷
    • 静脉注射
    • 口服途径

9. 病毒载体製造市场（依技术）

  • 介绍
  • 净化技术
    • 层析法
    • 超过滤
  • 转染方法
    • 基于化学
    • 电穿孔

第 10 章病毒载体製造市场（按适应症）

  • 介绍
  • 心血管疾病
  • 遗传性疾病
  • 感染疾病
  • 代谢紊乱

第 11 章病毒载体製造市场（按应用）

  • 介绍
  • 基因治疗
    • 遗传性疾病
    • 肿瘤疾病
    • 单基因突变
  • 肿瘤监测
    • 基因惰性
    • 溶瘤病毒疗法
    • 肿瘤抑制基因
  • 疫苗
    • 癌症疫苗
    • 感染疾病
    • 通用感染疾病

第 12 章病毒载体製造市场（依最终用户）

  • 介绍
  • 生技公司
    • 大型企业
    • Start-Ups
  • 製药公司
    • 製造业
    • 研究与开发
  • 研究所
    • 学术实验室
    • 政府实验室

13.美洲病毒载体製造市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

14. 亚太病毒载体製造市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

15. 欧洲、中东和非洲病毒载体製造市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • ABL Inc.
  • Batavia Biosciences BV by CJ Cheiljedang
  • Biovian Oy
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • Danaher Corporation
  • FinVector Oy
  • FUJIFILM Diosynth BIoTechnologies USA, Inc.
  • GE HealthCare Technologies, Inc.
  • Genezen Laboratories, Inc.
  • Kaneka Eurogentec SA
  • Lonza Group Ltd.
  • MaxCyte, Inc.
  • Merck KGaA
  • Miltenyi BIoTec GmbH
  • Novartis AG
  • Oxford Biomedica PLC
  • Sanofi SA
  • Sirion-BIoTech GmbH
  • Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uniQure NV
  • VGXI, Inc. by GeneOne Life Science
  • Waisman Biomanufacturing
  • Wuxi AppTec Co., Ltd.
Product Code: MRR-FD3F12D54086

The Viral Vector Manufacturing Market was valued at USD 9.19 billion in 2024 and is projected to grow to USD 11.00 billion in 2025, with a CAGR of 20.03%, reaching USD 27.50 billion by 2030.

Introduction

KEY MARKET STATISTICS
Base Year [2024] USD 9.19 billion
Estimated Year [2025] USD 11.00 billion
Forecast Year [2030] USD 27.50 billion
CAGR (%) 20.03%

In recent years, the dynamic field of viral vector manufacturing has emerged as a cornerstone of advanced therapeutics and breakthrough biomedical research. The convergence of innovative technology, rigorous scientific inquiry, and evolving regulatory frameworks has accelerated the development and application of viral vectors in diverse therapeutic areas. This transformative landscape is characterized by robust growth fueled by an increasing demand for personalized medicine, gene therapies, and vaccines. Surgical precision in process optimization and stringent quality control measures ensure that these vectors meet the highest standards of safety and efficacy.

From research laboratories to clinical settings, the ability to deliver targeted treatments depends on sophisticated manufacturing processes that are continuously refined. Advances in both upstream and downstream processing have enabled manufacturers to achieve scalability and operational efficiency without compromising product integrity. Consequently, a substantial body of market research now underscores the importance of leveraging state-of-the-art production techniques and regulatory compliance as the industry marches toward a future where biotherapeutics become even more accessible and effective.

The journey of viral vector manufacturing is not only one of technological sophistication but also of strategic market positioning. With heightened investor interest and the integration of digital technologies in quality assurance, the ecosystem is primed for sustained innovation and broader applications in various disease domains. This introductory overview sets the stage for an in-depth exploration into the multifaceted segments, emerging trends, and key regional and corporate initiatives that define the manufacturing landscape in this rapidly evolving field.

Transformative Shifts in the Landscape

The current environment in viral vector manufacturing is witnessing transformative shifts that are reshaping how both established industry players and emerging companies approach production challenges and market opportunities. Rapid technological advancements and the integration of next-generation bioprocessing techniques have revolutionized the way vectors are engineered, optimized, and deployed. Industrial leaders have continually adapted to these changes by adopting modular production strategies and leveraging process automation, which together streamline scalability while meeting exacting regulatory benchmarks.

Significant developments in automation and real-time analytics have ushered in a new era of operational efficiency. This evolving landscape now places greater emphasis on process integration across multiple stages of production, leading to the consolidation of formerly siloed workflows. In parallel, evolving regulatory and quality assurance frameworks continue to push manufacturers toward rigorous validation methods, ensuring that even the most complex products can be rapidly scaled without compromising on quality or safety.

Beyond the technological paradigms, a noticeable trend is the diversification of business models. Many companies are shifting from traditional, linear production pathways to more agile and customizable platforms that can respond flexibly to market demands. Strategic investments in emerging subfields - such as advanced purification techniques and novel transfection methodologies - are not only redefining product lifecycles but are also setting new benchmarks for clinical success and commercial viability. This period of unprecedented change highlights the need for continuous strategic reassessment and innovation, which not only fosters operational excellence but also offers a competitive edge in capturing global market opportunities.

Moreover, industry trends reflect an increasing acknowledgement of both the operational challenges and the tremendous opportunities presented by the biologics manufacturing landscape. The emphasis is now firmly on integrating digital solutions with traditional production techniques, thereby creating a hybrid model that is resilient to market fluctuations and adaptable to evolving research requirements. In sum, these transformative shifts are paving the way for a future where viral vector manufacturing not only meets the growing global health demands but does so through a lens of efficiency, sustainability, and precision.

Key Segmentation Insights

The market for viral vector manufacturing is intricately segmented, allowing stakeholders to pinpoint areas of significant innovation and opportunity. A detailed examination of segmentation based on vector type reveals a broad array of approaches, including the study of adenoviral vectors, baculoviral vectors, herpes simplex vectors, lentiviral vectors, plasmid DNA, and retrovirus. These specific categories underscore the varied genetic elements and delivery mechanisms employed in targeted therapies and are critical for tailoring production strategies to clinical needs.

Moving beyond vector type, the market introduces segmentation based on workflow processes which feature a dichotomy of downstream and upstream processing. Downstream processing is methodically divided into formulation and purification, each critical for maintaining product stability and regulatory compliance. On the other hand, upstream processing is further categorized by the use of bioreactors, cell culture systems, and tailored media formulations, enabling a high degree of customization in the scaling and optimization of vector production.

Furthermore, a nuanced approach to segmentation based on the delivery method highlights the dual strategies of ex vivo and in vivo applications. In the ex vivo domain, the focus on cell re-infusion and cell transduction techniques optimizes the integration of therapeutic vectors within target cells outside of the human body. Conversely, in vivo methodologies, which include direct injection, the intravenous route, and oral administration, are pivotal in ensuring efficient vector delivery and transgene expression in living organisms. Each route presents unique challenges and advantages that require specific operational and clinical considerations.

The segmentation based on technology further adds layers of sophistication to the market analysis. It encompasses purification techniques and transfection methods, with the former subdivided into chromatography and ultrafiltration. The latter is dissected into chemical-based approaches and electroporation, each offering distinct operational benefits and technical challenges when considering product yield and purity. Such detailed segmentation highlights the importance of tailored manufacturing processes that can adapt to the evolving demands of clinical and industrial applications.

Additionally, market segmentation by disease indication provides insights into the diverse therapeutic landscapes being addressed. The focus spans across cardiovascular diseases, genetic disorders, infectious diseases, and metabolic disorders, with each indication necessitating a specialized approach in vector design and production. Moreover, the application-based segmentation offers a granular view of the market dynamics by focusing on gene therapy, oncology research, and vaccinology. In gene therapy, further classification into inherited disorders, oncological disorders, and single gene mutations reveals targeted approaches to personalized medicine. Similarly, the domain of oncology research is explicated through subdivisions like gene inactivation, oncolytic virotherapy, and tumor suppressor genes, while vaccinology is mapped through the realms of cancer vaccines, infectious diseases, and zoonotic diseases.

Lastly, market segmentation based on end user profiles provides crucial insights regarding the diverse demand in the industry. The analysis spans biotechnology companies and pharmaceutical companies, along with research institutions. The biotechnology segment itself is further divided into large enterprises and start-ups, while pharmaceutical companies focus on the dual realms of manufacturing and research and development. Equally, the research institutions are bifurcated into academic laboratories and government labs. This level of segmentation not only allows stakeholders to effectively allocate resources and optimize production methodologies but also drives targeted innovation that is closely aligned with both clinical and commercial imperatives.

Based on Vector Type, market is studied across Adenoviral Vectors, Baculoviral Vectors, Herpes Simplex Vectors, Lentiviral Vectors, Plasmid DNA, and Retrovirus.

Based on Workflow, market is studied across Downstream Processing and Upstream Processing. The Downstream Processing is further studied across Formulation and Purification. The Upstream Processing is further studied across Bioreactors, Cell Culture Systems, and Media Formulations.

Based on Delivery Method, market is studied across Ex Vivo and In Vivo. The Ex Vivo is further studied across Cell Re-infusion and Cell Transduction. The In Vivo is further studied across Direct Injection, Intravenous Route, and Oral Administration.

Based on Technology, market is studied across Purification Techniques and Transfection Methods. The Purification Techniques is further studied across Chromatography and Ultrafiltration. The Transfection Methods is further studied across Chemical-Based and Electroporation.

Based on Disease Indication, market is studied across Cardiovascular Diseases, Genetic Disorders, Infectious Diseases, and Metabolic Disorders.

Based on Application, market is studied across Gene Therapy, Oncology Research, and Vaccinology. The Gene Therapy is further studied across Inherited Disorders, Oncological Disorders, and Single Gene Mutations. The Oncology Research is further studied across Gene Inactivation, Oncolytic Virotherapy, and Tumor Suppressor Genes. The Vaccinology is further studied across Cancer Vaccines, Infectious Diseases, and Zoonotic Diseases.

Based on End User, market is studied across Biotechnology Companies, Pharmaceutical Companies, and Research Institutions. The Biotechnology Companies is further studied across Large Enterprises and Start-Ups. The Pharmaceutical Companies is further studied across Manufacturing and Research and Development. The Research Institutions is further studied across Academic Laboratories and Government Labs.

Key Regional Insights

Regional analysis reveals that the Americas continue to be a significant market driver in viral vector manufacturing, leveraging strong research ecosystems, advanced infrastructure, and high consumer demand for innovative therapies. These regions are characterized by robust investment in state-of-the-art biomanufacturing facilities that support both early-stage development and full-scale production, ensuring that the therapeutic products meet stringent quality standards and regulatory benchmarks.

In Europe, the Middle East & Africa, the market is shaped by a confluence of regulatory modernization, academic excellence, and strategic partnerships across borders. This multi-regional landscape benefits from a well-established network of research institutions and clinical centers that collaboratively drive advancements in viral vector technologies. Emphasis on precision medicine and personalized treatment modalities in these regions is driving transformative investments, particularly in emerging gene therapies and innovative vaccine developments.

The Asia-Pacific region, meanwhile, is emerging as a critical hub for both research and manufacturing excellence. Rapid industrial growth, coupled with an expanding base of skilled professionals and strong governmental support, is propelling the expansion of manufacturing capacities. The region's market dynamics are notably influenced by the accelerated adoption of advanced technologies, increased investment in research and development, and strategic initiatives aimed at capturing both domestic and international market shares. Integration of cutting-edge analytics and digital solutions further reinforces the potential for scalable, cost-effective production techniques that resonate with global demands.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

A comprehensive analysis of the market underscores the influence of several key players that have been instrumental in shaping the viral vector manufacturing landscape. Industry frontrunners such as ABL Inc. and Batavia Biosciences B.V. by CJ Cheiljedang are recognized for their innovative approaches and robust R&D frameworks. Companies like Biovian Oy and Charles River Laboratories International, Inc. have set exemplary standards in quality control and regulatory compliance, powering the development of next-generation therapeutics. Creative Biogene and Danaher Corporation also hold pivotal roles in advancing operational efficiencies through advanced process optimization techniques.

Additional noteworthy contributors such as FinVector Oy and FUJIFILM Diosynth Biotechnologies U.S.A., Inc. continually demonstrate strategic prowess through their investments in both cutting-edge technology and process automation. GE HealthCare Technologies, Inc. and Genezen Laboratories, Inc. are industry examples of organizations repurposing traditional manufacturing techniques into innovative, scalable solutions that address modern therapeutic demands. Alongside these, established names like Kaneka Eurogentec S.A., Lonza Group Ltd., and MaxCyte, Inc. provide comprehensive insights into the art of effective vector management and production strategy.

The influence of multinational giants like Merck KGaA, Miltenyi Biotec GmbH, Novartis AG, and Oxford Biomedica PLC further underscores the international drive towards excellence in viral vector production. Their contributions extend beyond traditional manufacturing to encompass advanced research, leading-edge technology integration, and holistic quality assurance processes. Likewise, pharmaceutical heavyweights such as Sanofi SA and Sirion-Biotech GmbH inject deep knowledge of market demands and clinical efficacies into production pipelines. In parallel, Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd., Takara Bio Inc., and Thermo Fisher Scientific Inc. have consistently navigated the intricate balance between innovation and regulatory compliance. Companies such as uniQure N.V., VGXI, Inc. by GeneOne Life Science, Waisman Biomanufacturing, and Wuxi AppTec Co., Ltd. round out the spectrum of industry leaders that collectively drive progress, research, and market penetration in the viral vector manufacturing sphere.

The report delves into recent significant developments in the Viral Vector Manufacturing Market, highlighting leading vendors and their innovative profiles. These include ABL Inc., Batavia Biosciences B.V. by CJ Cheiljedang, Biovian Oy, Charles River Laboratories International, Inc., Creative Biogene, Danaher Corporation, FinVector Oy, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., GE HealthCare Technologies, Inc., Genezen Laboratories, Inc., Kaneka Eurogentec S.A., Lonza Group Ltd., MaxCyte, Inc., Merck KGaA, Miltenyi Biotec GmbH, Novartis AG, Oxford Biomedica PLC, Sanofi SA, Sirion-Biotech GmbH, Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd., Takara Bio Inc., Thermo Fisher Scientific Inc., uniQure N.V., VGXI, Inc. by GeneOne Life Science, Waisman Biomanufacturing, and Wuxi AppTec Co., Ltd.. Actionable Recommendations for Industry Leaders

Successful adaptation in the fast-paced viral vector manufacturing environment hinges on a combination of strategic investments in technology, operational optimization, and proactive market engagement. It is essential that industry leaders continuously monitor emerging trends and invest in research and development initiatives that not only streamline production processes but also enhance product quality and compliance with evolving regulatory standards.

To maintain a competitive edge, companies should consider investing in digital transformation strategies that integrate advanced data analytics with traditional production workflows. This proactive approach will help streamline process optimization, reduce operational costs, and enhance overall product consistency. Simultaneously, fostering strategic partnerships with academic institutions and technology providers can catalyze innovation and facilitate access to breakthrough methodologies.

It is also advisable to focus on modular manufacturing platforms that are designed to be flexible and responsive to market fluctuations. This operational agility supports quick scaling in response to increased demand and ensures that production pipelines remain robust in the face of supply chain disruptions. Additionally, prioritizing innovations in both purification techniques and transfection methods through targeted capital expenditure will further improve yield and efficiency across both upstream and downstream processes.

Stakeholders should also evaluate the evolving regulatory landscape and invest in compliance frameworks that integrate seamlessly with existing quality systems. By emphasizing validation and real-time monitoring protocols, companies can reduce the risk of production delays and ensure that products adhere to the highest safety and efficacy standards. Ultimately, a forward-thinking and agile approach to process innovation, coupled with a focus on strategic regional and technological investments, will position industry leaders at the forefront of tomorrow's therapeutic breakthroughs.

Conclusion

In summary, the viral vector manufacturing landscape is characterized by rapid transformation, underpinned by a convergence of technological innovation, strategic segmentation, and extensive regional diversification. The comprehensive segmentation insights discussed reveal how differences in vector types, workflows, delivery methods, technological applications, disease indications, and end user profiles collectively contribute to a multi-dimensional market dynamic. This layered understanding equips stakeholders with a granular perspective on both the opportunities and challenges prevalent in the sector.

The regional analysis further emphasizes how market nuances differ across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region contributing uniquely to the overall growth trajectory. When combined with insights into the key companies driving market advancements, the holistic picture points to a future where flexibility, innovation, and precision in viral vector production will continue to shape the success of therapeutic solutions.

The evolving trends not only indicate improved operational efficiencies and robust manufacturing protocols but also highlight the importance of agile and forward-thinking strategies in navigating this competitive arena. Ultimately, the landscape is primed for sustained growth, and this concluding overview underscores the imperative for strategic investments and agile methodologies to secure leadership in an increasingly dynamic market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of viral vectors in vaccine production against infectious diseases
      • 5.1.1.2. Growing emphasis on personalized medicine and gene therapy
      • 5.1.1.3. Supportive government initiatives bolstering viral vector manufacturing capabilities globally
    • 5.1.2. Restraints
      • 5.1.2.1. High production costs and inconsistencies in raw materials
    • 5.1.3. Opportunities
      • 5.1.3.1. Enhancement of gene therapy solutions for structural and functional retinal diseases
      • 5.1.3.2. Investment in scalable manufacturing processes for high-volume production of viral vectors
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscapes ensuring compliance with varying standards worldwide
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Vector Type: Rising utilization of adenoviral vector in vaccines and gene therapy owing to strong immunogenic profile and ability to infect non-dividing cells
    • 5.2.2. Application: Rising demand for gene therapy for treating inherited disorders and oncological disorders
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Viral Vector Manufacturing Market, by Vector Type

  • 6.1. Introduction
  • 6.2. Adenoviral Vectors
  • 6.3. Baculoviral Vectors
  • 6.4. Herpes Simplex Vectors
  • 6.5. Lentiviral Vectors
  • 6.6. Plasmid DNA
  • 6.7. Retrovirus

7. Viral Vector Manufacturing Market, by Workflow

  • 7.1. Introduction
  • 7.2. Downstream Processing
    • 7.2.1. Formulation
    • 7.2.2. Purification
  • 7.3. Upstream Processing
    • 7.3.1. Bioreactors
    • 7.3.2. Cell Culture Systems
    • 7.3.3. Media Formulations

8. Viral Vector Manufacturing Market, by Delivery Method

  • 8.1. Introduction
  • 8.2. Ex Vivo
    • 8.2.1. Cell Re-infusion
    • 8.2.2. Cell Transduction
  • 8.3. In Vivo
    • 8.3.1. Direct Injection
    • 8.3.2. Intravenous Route
    • 8.3.3. Oral Administration

9. Viral Vector Manufacturing Market, by Technology

  • 9.1. Introduction
  • 9.2. Purification Techniques
    • 9.2.1. Chromatography
    • 9.2.2. Ultrafiltration
  • 9.3. Transfection Methods
    • 9.3.1. Chemical-Based
    • 9.3.2. Electroporation

10. Viral Vector Manufacturing Market, by Disease Indication

  • 10.1. Introduction
  • 10.2. Cardiovascular Diseases
  • 10.3. Genetic Disorders
  • 10.4. Infectious Diseases
  • 10.5. Metabolic Disorders

11. Viral Vector Manufacturing Market, by Application

  • 11.1. Introduction
  • 11.2. Gene Therapy
    • 11.2.1. Inherited Disorders
    • 11.2.2. Oncological Disorders
    • 11.2.3. Single Gene Mutations
  • 11.3. Oncology Research
    • 11.3.1. Gene Inactivation
    • 11.3.2. Oncolytic Virotherapy
    • 11.3.3. Tumor Suppressor Genes
  • 11.4. Vaccinology
    • 11.4.1. Cancer Vaccines
    • 11.4.2. Infectious Diseases
    • 11.4.3. Zoonotic Diseases

12. Viral Vector Manufacturing Market, by End User

  • 12.1. Introduction
  • 12.2. Biotechnology Companies
    • 12.2.1. Large Enterprises
    • 12.2.2. Start-Ups
  • 12.3. Pharmaceutical Companies
    • 12.3.1. Manufacturing
    • 12.3.2. Research and Development
  • 12.4. Research Institutions
    • 12.4.1. Academic Laboratories
    • 12.4.2. Government Labs

13. Americas Viral Vector Manufacturing Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Viral Vector Manufacturing Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Viral Vector Manufacturing Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Abselion secures GBP 1.1 Million to develop next-gen cell platform for viral vector production
    • 16.3.2. Charles River Laboratories launches innovative viral vector tech transfer program to optimize gene therapy development
    • 16.3.3. Andelyn Biosciences partners with FNIH to accelerate gene therapy for rare diseases through innovative AAV manufacturing
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ABL Inc.
  • 2. Batavia Biosciences B.V. by CJ Cheiljedang
  • 3. Biovian Oy
  • 4. Charles River Laboratories International, Inc.
  • 5. Creative Biogene
  • 6. Danaher Corporation
  • 7. FinVector Oy
  • 8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 9. GE HealthCare Technologies, Inc.
  • 10. Genezen Laboratories, Inc.
  • 11. Kaneka Eurogentec S.A.
  • 12. Lonza Group Ltd.
  • 13. MaxCyte, Inc.
  • 14. Merck KGaA
  • 15. Miltenyi Biotec GmbH
  • 16. Novartis AG
  • 17. Oxford Biomedica PLC
  • 18. Sanofi SA
  • 19. Sirion-Biotech GmbH
  • 20. Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
  • 21. Takara Bio Inc.
  • 22. Thermo Fisher Scientific Inc.
  • 23. uniQure N.V.
  • 24. VGXI, Inc. by GeneOne Life Science
  • 25. Waisman Biomanufacturing
  • 26. Wuxi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. VIRAL VECTOR MANUFACTURING MARKET MULTI-CURRENCY
  • FIGURE 2. VIRAL VECTOR MANUFACTURING MARKET MULTI-LANGUAGE
  • FIGURE 3. VIRAL VECTOR MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 4. VIRAL VECTOR MANUFACTURING MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 21. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 25. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 30. VIRAL VECTOR MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 31. VIRAL VECTOR MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VIRAL VECTOR MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VIRAL VECTOR MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BACULOVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL CULTURE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MEDIA FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL RE-INFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL TRANSDUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DIRECT INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INTRAVENOUS ROUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHEMICAL-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INHERITED DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SINGLE GENE MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE INACTIVATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TUMOR SUPPRESSOR GENES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ZOONOTIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY START-UPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 79. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 80. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 81. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 82. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 83. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 84. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 86. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 87. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 90. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 91. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 94. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 95. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 96. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 97. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 99. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 100. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 101. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 102. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 103. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 104. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 106. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 107. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 111. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 114. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 115. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 116. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 118. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 119. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 120. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 121. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 122. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 123. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 125. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 126. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 130. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 133. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 134. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 135. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 137. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 138. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 139. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 140. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 141. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 142. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 144. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 145. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 149. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 152. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 153. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 154. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 156. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 157. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 158. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 159. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 160. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 161. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 163. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 164. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 167. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 168. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 171. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 172. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 173. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 175. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 176. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 177. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 178. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 213. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 215. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 216. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 217. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 218. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 219. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 220. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 222. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 223. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 227. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 230. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 231. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 232. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 234. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 235. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 236. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 237. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 238. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 239. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 241. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 242. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 245. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 246. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 247. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 249. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 250. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 251. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 253. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 254. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 255. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 256. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 257. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 258. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 259. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 260. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 261. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 262. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 265. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 266. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 268. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 269. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 270. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 272. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 273. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 274. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 275. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 276. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 277. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 278. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 279. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 280. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 281. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 283. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 284. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 285. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 287. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 288. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 289. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 291. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 292. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 293. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 294. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 295. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
  • TABLE 296. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 298. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 299. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 300. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 302. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 303. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
  • TABLE 304. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 305. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 306. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 307. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
  • TABLE 308. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 310. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 311. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 312. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 313. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
  • TABLE 314. MALAYSIA VIRAL VECTOR MANUFACTUR